MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
5.22
-0.15
-2.79%
Opening 12:20 05/15 EDT
OPEN
5.25
PREV CLOSE
5.37
HIGH
5.35
LOW
5.06
VOLUME
645.30K
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
1.670
MARKET CAP
855.27M
P/E (TTM)
-4.2946
1D
5D
1M
3M
1Y
5Y
1D
Annexon director William H. Carson acquires 8,000 shares for $46,240
PUBT · 1d ago
Annexon Price Target Announced at $7.00/Share by Goldman Sachs
Dow Jones · 3d ago
Annexon Initiated at Neutral by Goldman Sachs
Dow Jones · 3d ago
Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7
Benzinga · 3d ago
Annexon initiated with a Neutral at Goldman Sachs
TipRanks · 3d ago
Weekly Report: what happened at ANNX last week (0504-0508)?
Weekly Report · 4d ago
Annexon Biosciences (ANNX) Gets a Buy from Bank of America Securities
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN)
TipRanks · 05/08 14:50
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.